Open access journal of the Ferrata-Storti Foundation, a non-profit organization
Search results are limited to:
Abstract Book of the 7th European Myeloma Network Meeting, Prague, 16-18 April 2026
Vol. 111 No. s2
Showing matches for the individual search terms you entered. To search for an exact phrase, enclose your query in quotes.
Advanced filters
Search the full archive
Keyword matches

B01 | TIME-RESOLVED MULTI-LAYERED PROFILING IDENTIFIES RESOLUTION OF RIBOSOME COLLISIONS AND TRANSLATIONAL RECOVERY AS MECHANISMS CONTRIBUTING TO PROTEASOME INHIBITOR RESISTANCE (335 Online Views)

J. Zhou1, N.T. Crump1, M. Román-Trufero1|2, H.W. Auner1|2|3

1 Department of Immunology and Inflammation, Imperial College London, UK
2 Division of Haematology and Central Haematology Laboratory, Lausanne University Hospital, Switzerland
3 Faculty of Biology and Medicine, University of Lausanne, Switzerland
Proteasome Inhibitor Resistance Carfilzomib Multiple Myeloma

P54 | EVOLVING OUTCOMES IN MULTIPLE MYELOMA REAL-WORLD PRACTICE: 30-YEARS SINGLE CENTER EXPERIENCE (145 Online Views)

G. Giunta1, C. Bellofiore2, E. Scalisi1, V. Del Fabro3, F. Elia1|2, B. Garibaldi2, C. Finocchiaro1, F. Di Raimondo1|2, A. Romano1|2, C. Conticello2

1 Postgraduate School of Hematology, University of Catania, Italy
2 Division of Hematology, Azienda Policlinico-S. Marco, University of Catania, Italy
3 Faculty of Medicine and Surgery, “Kore” University of Enna, Italy
Multiple myeloma Real-World Practice Sicily

P31 | PROGNOSTIC IMPACT OF INTERPHASE FISH IN MULTIPLE MYELOMA: SINGLE-CENTER IRISH EXPERIENCE (183 Online Views)

T. Pramod1, A. Bannaga1, S. Kumar1, B. Hennessy1, E. E. Hassadi1

1 University Hospital Waterford, Ireland
Multiple Myeloma Prognostic factors FISH abnormalities

P32 | MULTIPLE MYELOMA PRESENTING AS ACUTE BACK PAIN AND KIDNEY INJURY: A DIAGNOSTIC CHALLENGE (196 Online Views)

M. Hammad1, O. Elsegai2

1 Royal Preston Hospital, Preston, UK
2 Salmaniya Medical Complex, Manama, Bahrain
Multiple Myeloma Musculoskeletal symptoms Renal Impairment

P34 | CEVOSTAMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: BIOMARKER ANALYSES FROM CAMMA 1 ARM B (188 Online Views)

R. Popat1, S. Harrison2, C. H. Riley3, H.S. Mian4, A. Spencer5, N. Lavi6, L. Paris7, T. Jelínek8, M. Szarejko9, S. Grosicki10, K. Kim11, I. Sandhu12, S. Chebon13, T. Tyagi14, P. Sewpaul15, L. Richardson15, K. Trunzer13, A. Mishra14, S. Trudel16

1 University College London Hospitals NHS Foundation Trust, UK
2 Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, Melbourne University and The Royal Melbourne Hospital, Australia
3 Rigshospitalet, Copenhagen, Denmark
4 McMaster University, Hamilton, Canada
5 Alfred Health-Monash University, Melbourne, Australia
6 Rambam Health Care Campus, Haifa, Israel
7 ASST Papa Giovanni XXIII, Bergamo, Italy
8 Department of Hematooncology, University Hospital Ostrava and University of Ostrava, Czech Republic
9 Medical University of Gdansk, Poland
10 Medical University of Silesia, Katowice, Poland
11 Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea
12 Cross Cancer Institute, University of Alberta, Edmonton, Canada
13 F. Hoffmann-La Roche Ltd, Basel, Switzerland
14 Genentech, Inc, South San Francisco, USA
15 Roche Products Ltd, Welwyn, UK
16 Princess Margaret Cancer Centre and University of Toronto, Canada
CAMMA 1 study BCMA Multiple Myeloma

P36 | EFFECTIVENESS OF BRIDGING THERAPY CORRESPONDS TO IMPROVED OUTCOMES AFTER CILTACABTAGENE AUTOLEUCEL: PHASE 3 CARTITUDE-4 STUDY OF PATIENTS WITH RELAPSED, LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA (227 Online Views)

E. Zamagni1, B. Dhakal2, S. Iida3, M.H. Sidiqi4|5, S.S. Yoon6, N. Callander7, C. Touzeau8|9|10|11, Q. Li12, A. Balogh12, A. Slaughter12, N. Benachour12, C. Lonardi12, A. Ghosh12, M. Vogel12, N. Lendvai12, T. Lengil12, M. Koneru13, N. Patel13, O. Costa Filho13, V. Mahajan13, J. Martínez-López14, K. Yong15, K. Weisel16, X. Leleu17

1 University of Bologna, Italy
2 Medical College of Wisconsin, Milwaukee, USA
3 Nagoya City University, Japan
4 Fiona Stanley Hospital, Perth, Australia
5 Curtin University, Perth, Australia
6 Seoul National University, Korea
7 University of Wisconsin, Madison, USA
8 Centre Hospitalier Universitaire Hotel Dieu, Nantes, France
9 Université d’Angers, Nantes, France
10 Université de Nantes, France
11 French Ministry of Health, Nantes, France
12 Johnson & Johnson
13 Legend Biotech USA Inc, Somerset, USA
14 Complutense University, Madrid, Spain
15 University College London, UK
16 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
17 CHU Poitiers, France
Multiple Myeloma CARTITUDE-4

P37 | ANALYSIS OF PATIENTS WITH PRIOR BCMA-TARGETED THERAPY AND THOSE ACHIEVING COMPLETE RESPONSE IN REALiTAL: A MULTI-COUNTRY OBSERVATIONAL STUDY OF TALQUETAMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA OUTSIDE OF CLINICAL TRIALS (246 Online Views)

R. Popat1, K.M. Kortüm2, H. Magen3, V. Mykytiv4, C. Liberatore5, E. Zamagni6, M.C. Da Vià7, E. Antonioli8, M. Hansson9, D. Santra10, D. Greer10, K. Subrt11, P. Hu11, E. Aeby11, N. Francella11, N.M. Suñe11, A. Perrot12, K. Uttervall13

1 University College London Hospitals NHS Foundation Trust, UK
2 University Hospital of Würzburg, Germany
3 Tel Aviv University, Israel
4 Cork University Hospital, Ireland
5 Ospedale Santo Spirito, Pescara, Italy
6 University of Bologna, Italy
7 IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
8 Careggi Hospital and University of Florence, Italy
9 Sahlgrenska University Hospital, Gothenburg, Sweden
10 Parexel International
11 Johnson & Johnson
12 Université de Toulouse, France
13 Karolinska University Hospital, Stockholm, Sweden
Multiple Myeloma REALiTAL Trial RRMM

P39 | RANDOMIZED PHASE II DOSE OPTIMIZATION STUDY OF INOBRODIB (CCS1477) IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (193 Online Views)

E. Searle1, V. Campbell2, C. Pawlyn3, D. Vogl4, S. Holstein5, S. Gooding6, M. Jenner7, T. Creasey8, A. Chaidos9, P. Rodríguez-Otero10, F. Al-Kaisi11, A. Brearton12, S. Moore6, J. O’Nions13, T. Somervaille1, T. Knurowski14, K. Clegg14, S. Paul14, K. Frese14, N. Joseph15

1 The Christie NHS Foundation Trust, Manchester, UK
2 Western General Hospital, Edinburgh, UK
3 The Royal Marsden NHS Foundation Trust, London, UK
4 Hospital of the University of Pennsylvania, Philadelphia, USA
5 University of Nebraska Medical Center, Omaha, USA
6 Oxford University Hospitals NHS Foundation Trust, Oxford, UK
7 University Hospital Southampton NHS Foundation Trust, UK
8 Northern Centre for Cancer Care, Newcastle upon Tyne, UK
9 Imperial College Healthcare NHS Trust, London, UK
10 Clínica Universidad de Navarra, Pamplona, Spain
11 Royal Derby Hospital, UK
12 The Clatterbridge Cancer Centre, Liverpool, UK
13 University College London Hospital, UK
14 CellCentric Ltd, Cambridge, UK
15 Emory Winship Cancer Institute, Atlanta, USA
Multiple Myeloma Inobrodib RRMM

P40 | EFFICACY AND SAFETY OF TALQUETAMAB + TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND EXTRAMEDULLARY DISEASE: UPDATED PHASE 2 RESULTS FROM THE RedirecTT-1 STUDY WITH EXTENDED FOLLOW-UP (213 Online Views)

M.V. Mateos1, P. Rodríguez-Otero2, S.Z. Usmani3, S. Kumar4, J.C. Ye5, S. Atrash6, H. Magen7, H. Quach8, M.P. Chu9, S. Trudel10, J. Richter11, H. Chuah12, M. Gatt13, E. Medvedova14, S. Raza15, D.H. Yoon16, T. Ishida17, J.V. Matous18, L. Rosiñol19, K. Onodera20, C. Maffucci21, E. Scott21, C. Heuck21, J. Zhang21, T. Henninger21, L. O’Rourke21, P. Thakkar21, M. Festa21, L. Huang21, J. Zhou21, M. Takamoto21, L. Pei21, J. Lu21, N. Au21, M. Krevvata21, Y.C. Cohen7

1 University Hospital of Salamanca, Spain
2 Cancer Center Clínica Universidad de Navarra, Pamplona, Spain
3 Memorial Sloan Kettering Cancer Center, New York, USA
4 Mayo Clinic Rochester, USA
5 University of Texas, Houston, USA
6 Levine Cancer Institute-Atrium Health, Charlotte, USA
7 Tel Aviv University, Israel
8 University of Melbourne, Australia
9 Alberta Health Services, Edmonton, Canada
10 Princess Margaret Cancer Centre, Toronto, Canada
11 Mount Sinai Medical Center, New York, USA
12 Royal Perth Hospital, Australia
13 Hebrew University of Jerusalem, Israel
14 Oregon Health and Science University, Portland, USA
15 Cleveland Clinic, USA
16 University of Ulsan College of Medicine, Seoul, Korea
17 Japanese Red Cross Medical Center, Tokyo, Japan
18 Colorado Blood Cancer Institute, Denver, USA
19 Hospital Clínic de Barcelona, Spain
20 Tohoku University Hospital, Sendai, Japan
21 Johnson & Johnson
Multiple Myeloma RedirecTT-1 trial RRMM

P42 | COMPARATIVE EFFECTIVENESS OF TECLISTAMAB IN REALiTEC VS. REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY IN LOCOMMOTION AND MOMMENT IN TRIPLE-CLASS EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA (166 Online Views)

A. Perrot1, M. Kortüm2, R. Popat3, K. Uttervall4, M.V. Mateos5, K. Weisel6, K. Van Nimwegen7, J. Diels7, F. Ong7, R. Morano7, E. Rubio-Azpeitia7, P. Moreau8

1 Universite de Toulouse, France
2 University Hospital of Würzburg, Germany
3 University College London Hospitals NHS Foundation Trust, UK
4 Karolinska University Hospital, Stockholm, Sweden
5 Hospital Universitario de Salamanca, Spain
6 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
7 Johnson & Johnson
8 University Hospital Hôtel-Dieu, Nantes, France
Multiple Myeloma RRMM Teclistamab

P43 | SELINEXOR, MEZIGDOMIDE, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RELAPSED OR ARE INELIGIBLE FOR T-CELL–REDIRECTING THERAPY: STOMP PHASE 1 PRELIMINARY RESULTS (196 Online Views)

C. Mo1, C. Gasparetto2, C. Costa2, A.J. Cowan3, T. Mark4, Y. Chai4, T. Kashyap4, J. Katz5, M. Amatangelo5, P.G. Richardson1

1 Dana-Farber Cancer Institute, Boston, USA
2 Duke Cancer Institute, Durham, USA
3 University of Washington, Seattle, USA
4 Karyopharm Therapeutics, Newton, USA
5 Bristol Myers Squibb, Princeton, USA
Multiple Myeloma RRMM STOMP trial

P45 | MODELING DORMANCY IN MULTIPLE MYELOMA: FUNCTIONAL AND TRANSCRIPTOMIC CHARACTERIZATION OF SERUM STARVATION AND CHEMOTHERAPY-INDUCED STATES (191 Online Views)

Z.S. Najafabadi1, N. Afrin2, M. Helal2, H. Fischer1, M. John2, E. Stanojkovska1, J. Mersi1, S. Kadel1, J. Waldschmidt1, M. Kortüm1, K. Kretzschmar2, H. Einsele1, A. Riedel2, L. Rasche1|2

1 Internal Medicine II, Universitätsklinikum Würzburg, Germany
2 Mildred Scheel Early Career Centre for Cancer Research Würzburg, The Julius-Maximilians-Universität Würzburg, Germany
Multiple Myeloma Cancer cell dormancy 3D Model

P47 | UTILITY AND SENSITIVITY OF WETT-SA53 TO MEASURE DYSGEUSIA ASSOCIATED WITH TALQUETAMAB, A GPRC5D×CD3 BISPECIFIC ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY DATA FROM THE TALISMAN STUDY (211 Online Views)

R. Popat1, N.W.C.J. Van De Donk2|3, B. Faiman4, J. Yuda5, K. Kim6, A. Costa7, A. Laheij2|3, R.L. Doty8, J. Omel9, B. Lipe10, L. Sanchez11, A. Chari12, A. Lin13, H. Sroussi14, M. Fernandez15, K.S. Gray15, G. Aguilar15, K. Bolyard15, J. Schultz15, K. Qi15, D. Cortes-Selva15, J. Zhang15, C. Heuck15, K. Hawks15, K. Tian15, M. França15, L. Rasche16

1 University College London Hospitals NHS Foundation Trust, UK
2 Amsterdam University Medical Center, The Netherlands
3 Vrije Universiteit Amsterdam, The Netherlands
4 Cleveland Clinic, USA
5 National Cancer Center Hospital East, Kashiwa, Japan
6 Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
7 D’or Institute for Research and Education, São Paulo, Brazil
8 University of Pennsylvania Smell and Taste Center, Philadelphia, USA
9 The Central Nebraska Myeloma Support Group, Grand Island, USA
10 University of Rochester Medical Center, USA
11 Icahn School of Medicine at Mount Sinai, New York, USA
12 University of California, San Francisco, USA
13 University of Pennsylvania, Philadelphia, USA
14 Brigham and Women’s Hospital, and Harvard School of Dental Medicine, Boston, USA
15 Johnson & Johnson
16 University Hospital of Würzburg, Germany
TALISMAN study Multiple Myeloma RRMM

P48 | LONG-TERM PROGRESSION-FREE SURVIVAL BENEFIT WITH CILTACABTAGENE AUTOLEUCEL IN STANDARD-RISK RELAPSED/REFRACTORY MULTIPLE MYELOMA (213 Online Views)

D. Dytfeld1, L.J. Costa2, A. Oriol3, S. Manier4|5, P.M. Voorhees6, Y. Lin7, M. Htut8, W. Roeloffzen9, P. J. Ho10|11, U. Shah12|13, M. Zhao14, Q. Li15, A. Balogh15, K. Li15, A. Slaughter15, N. Benachour15, C. Lonardi15, A. Ghosh15, H. Sun15, N. Lendvai15, T. Lengil15, N. Patel16, M. Koneru16, E. Florendo16, O. C. Filho16, V. Mahajan16, P. Rodríguez-Otero17, C. Strouse18, A.K. Stewart19|20, S. Sidana21

1 Poznan University of Medical Sciences, Poznań, Poland
2 University of Alabama at Birmingham, USA
3 Hospital Germans Trias i Pujol, Barcelona, Spain
4 University of Lille, France
5 Centre Hospitalier Universitaire Lille, France
6 Wake Forest University, Charlotte, USA
7 Mayo Clinic, Rochester, USA
8 City of Hope Comprehensive Cancer Center, Duarte, USA
9 University Medical Center Groningen, The Netherlands
10 Royal Prince Alfred Hospital, Sydney, Australia
11 The University of Sydney, Australia
12 Memorial Sloan Kettering Cancer Center, New York, USA
13 Weill Cornell Medical College, New York, USA
14 IQVIA, Shangai, China
15 Johnson & Johnson
16 Legend Biotech USA Inc, Somerset, USA
17 Universidad de Navarra, Pamplona, Spain
18 University of Iowa, Iowa City, USA
19 University Health Network, Toronto, Canada
20 The Princess Margaret Cancer Centre, Toronto, Canada
21 Stanford University, USA
CARTITUDE-4 Multiple Myeloma Progression free

P50 | INPATIENT VS. OUTPATIENT TREATMENT MANAGEMENT WITH TECLISTAMAB IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A COST AND HEALTHCARE RESOURCE UTILIZATION ANALYSIS (205 Online Views)

N.W.C.J. Van De Donk1, R. Wester2, I. Nijhof3, C. Albrecht4, R. Morano5, C. Entrala6, K. Van Nimwegen1|2|3|4|5|6

1 Amsterdam University Medical Center, The Netherlands
2 Erasmus Medical Center, Rotterdam, The Netherlands
3 St. Antonius Ziekenhuis, Nieuwegein, The Netherlands
4 Johnson & Johnson, Paris, France
5 Johnson & Johnson, Madrid, Spain
6 Johnson & Johnson, Breda, The Netherlands
Multiple Myeloma RRMM Treatment Management

P55 | MANAGEMENT OF NEUROLOGICAL TOXICITIES OF PATIENTS TREATED WITH IMMUNOTHERAPIES FOR MULTIPLE MYELOMA: A SINGLE-CENTER REAL WORLD EXPERIENCE (177 Online Views)

E. Manzato1|2, M. Puppi1|2, M. Talarico1|2, M. Iezza1|2, S. Masci1|2, S. Ghibellini1|2, A. Vitale2, S. Barbato1|2, P. Tacchetti1, L. Pantani1, K. Mancuso1|2, E. Zamagni1|2

1 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia L. A. Seràgnoli, Italy
2 Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Italy
Multiple Myeloma Neurological Toxicities RRMM

P29 | PLATELET AGGREGATION AND THROMBIN GENERATION IN MULTIPLE MYELOMA: A PROSPECTIVE STUDY (176 Online Views)

M. Biglietto1, R. Mormile1, A. Piciocchi1, F. Fazio1, M. Capriata1, S. Sorella1, B. Mandelli1, D. Kasmi1, E. Baldacci1, A. Chistolini1, M.T. Petrucci1, C. Santoro1

1 Department of Translational and Precision Medicine, Sapienza University of Rome, Italy
Multiple Myeloma Platelet Functions NDMM

P58 | TRIAL IN PROGRESS: QUINTESSENTIAL-2 – A PHASE 3 STUDY OF ARLOCABTAGENE AUTOLEUCEL VS. STANDARD OF CARE IN ADULT PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA EXPOSED TO LENALIDOMIDE (210 Online Views)

E. Lebel1, A. Abdulgawad2, S. Bramanti3, G. Garate4, P.J. Ho5, M. Keränen6, Y. Cohen7, M. Vase8, A. Khot9, I. Kristensen10, R. Leblanc11, C. Lee12, W. Legiec13, H. Magen14, M.V. Mateos15, D. Oh16, L. Pour17, N. Schutz18, A. Spyridonidis19, K. Weisel20, J. Zaucha21, S. Larson22, A. Varshavsky-Yanovsky23, K. Grazioli24, D. Basudhar24, H. Hu24, Y. Meng24, L. Eldjerou24, S. Bal25, S. Harrison9, R. Popat26, M. Raab27, P. Rodriguez-Otero28

1 Hadassah Medical Center, Jerusalem, Israel
2 Christie NHS Foundation Trust, Manchester, UK
3 IRCCS Istituto Clinico Humanitas, Rozzano, Italy
4 Hospital Aleman, Buenos Aires, Argentina
5 Royal Prince Alfred Hospital and University of Sydney, Camperdown, Australia
6 Helsinki University Hospital, Finland
7 Tel Aviv Sourasky Medical Center and Faculty of Medical and Health Sciences, Tel Aviv University, Israel
8 Aarhus Universitetshospital, Midtjylland, Denmark
9 Peter MacCallum Cancer Centre, Royal Melbourne Hospital and University of Melbourne, Victoria, Australia
10 Odense Universitetshospital, Denmark
11 Hematology-Oncology and Cell Therapy University Institute, Hôpital Maisonneuve-Rosemont Research Center, Université de Montréal, Quebec, Canada
12 Royal Adelaide Hospital, Australia
13 St. John of Dukla Oncology Center of Lublin Land,Poland
14 Department of Hematology, Chaim Sheba Medical Center, Ramat-Gan, Faculty of Medicine, Tel Aviv University, Israel
15 Hospital Universitario de Salamanca, Spain
16 Monash Health and Monash University, Clayton, Victoria, Australia
17 Masaryk University and University Hospital Brno, Czech Republic
18 Hospital Italiano de Buenos Aires, Argentina
19 University Hospital of Patras, Greece
20 University Medical Center Hamburg-Eppendorf, Germany
21 Medical University of Gdańsk and University Clinical Center, Poland
22 UCLA Medical Center, Los Angeles, USA
23 Fox Chase Cancer Center Temple Health, Philadelphia, USA
24 Bristol Myers Squibb, Princeton, USA
25 University of Alabama at Birmingham, USA
26 University College London Hospital, UK
27 Universitaetsklinikum Heidelberg, Germany
28 Clinica Universidad de Navarra, Pamplona, Spain
QUINTESSENTIAL-2 Trial Multiple Myeloma RRMM

P59 | BISPECIFIC ANTIBODIES IN FRAIL AND ELDERLY MULTIPLE MYELOMA PATIENTS WITH ECOG >1: REAL-WORLD IMPACT OF PERFORMANCE STATUS AND DOSE MODIFICATIONS ON OUTCOMES (165 Online Views)

D. Stoumbos1, A. Antoniou1, K. Lampropoulos1, S. Chrysoglou1, C. Prifti1, M. Panagiotouni1, M. Dadakaridou1, S. Giourgouli2, K. Stefanidis3, M. Kotsopoulou1

1 Metaxa Cancer Hospital, Hematology Clinic and Bone Marrow Transplantation Unit, Athens, Greece
2 Metaxa Cancer Hospital, Nuclear Medicine Department, Athens, Greece
3 Metaxa Cancer Hospital, Department of Radiology, Athens, Greece
Multiple Myeloma Elderly Bispecific antibodies

P61 | IMMUNE EFFECTOR CELL COLITIS DURING TREATMENT WITH AN ANTI-BCMA BISPECIFIC ANTIBODIES (179 Online Views)

M. Minnema1, H. Fidder2, R. Oostvogels1, V. Biemans2

1 Department of Hematology, UMC Utrecht, The Netherlands
2 Department of Gastroenterology, UMC Utrecht, The Netherlands
Multiple Myeloma Colitis Bispecific antibodies

P62 | INITIAL EXPERIENCE WITH IDECABTAGENE VICLEUCEL IN PATIENTS WITH REFRACTORY MULTIPLE MYELOMA: CASE SERIES IN A TERTIARY CARE HOSPITAL (173 Online Views)

L. Piquer Monsonis1, A. Pérez Montaña1, J.M. Sánchez Raga1, A. Sampol Mayol1, M. Galí Sampol1, R. Ferrero Guillén1, E. Serrasoles Alemany1, M. Remezal Serrano1, A. Alonso Carballo1, S. Montolio Chiva1, P. Gómez Fernández1, J. Domínguez Esteve2, A. Horrillo Orejudo2

1 Department of Hematology and Hemotherapy, Hospital Universitari Son Espases, Palma de Mallorca, Spain
2 Hospital Comarcal de Inca, Spain
BCMA Decabtagene vicleucel Multiple Myeloma

P64 | ODISSEY: A MULTICENTER, OBSERVATIONAL STUDY OF MULTIPLE MYELOMA ITALIAN PATIENTS WHO DISCONTINUED THERAPY IN CLINICAL PRACTICE (184 Online Views)

N. Sgherza1, E. Antonioli2, E. Zamagni3|4, C. Conticello5, F. Fazio6, S. Palmieri7, A. Cagnetta8, G. Palumbo9, A.G. Solimando10, R. Della Pepa11, C. Germano12, G. Palazzo13, C. De Risi14, A. Quinto15, G. Buda16, M. Gentile17|18, O. Annibali19, D. De Novellis20, P. Curci1, O. Battisti1, L. Pavan21|22, M. Capriata6, G. Di Carlo13, G. Proietti6, V. Del Fabro23, A.P. Falcone24, R. Spadano25, D. Derudas26, G. Mele27, G. Barilà28, M.T. Petrucci6, F. Di Raimondo5|29, F. Albano1|30, P. Musto1|30

1 Hematology and Stem Cell Transplantation Unit, AOUC Policlinico, Bari, Italy
2 Hematology Unit, Careggi University Hospital, Firenze, Italy
3 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli", Italy
4 Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Italy
5 Division of Hematology and Stem Cell Transplantation, Policlinico“G. Rodolico-San Marco”, Catania, Italy
6 Department of Translational and Precision Medicine Hematology, Sapienza University, Roma, Italy
7 Hematology Unit, Ospedale Cardarelli, Napoli, Italy
8 Hematology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy
9 Hematology Unit, AOU Policlinico Riuniti di Foggia, Italy
10 G. Baccelli Unit of Internal Medicine, Department of Precision and Regenerative Medicine and Ionian Area-(DiMePRe-J), School of Medicine, University of Bari Aldo Moro, Italy
11 Department of Clinical Medicine and Surgery, University Federico II, Napoli,Italy
12 Hematology Unit,“Mons. Dimiccoli” Hospital, Barletta, Italy
13 Hematology Unit, “G. Moscati” Hospital, Taranto, Italy
14 Haematology and Transplant Unit, “V. Fazzi” Hospital, Lecce, Italy
15 Hematology and Cell Therapy Unit, IRCCS “G. Paolo II”, Bari, Italy
16 Department of Clinical and Experimental Medicine, Hematology, University of Pisa, Italy
17 Hematology Unit, Department of Onco-Hematology, AO of Cosenza, Italy
18 Department of Pharmacy, Health and Nutritional Science, University of Calabria, Italy
19 Hematology, Stem Cell Transplantation, Fondazione Policlinico Universitario Campus Biomedico di Roma, Italy
20 Hematology and Transplant Center, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy
21 Department of Medicine
22 (DIMED), Hematology section, Padua University School of Medicine, Italy
23 Faculty of Medicine and Surgery “Kore”, University of Enna, Italy
24 Department of Hematology and Bone Marrow Transplant, IRCSS Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Italy
25 Hematology Unit, Santo Spirito Hospital, Pescara, Italy
26 Department of Hematology, Businco Hospital, Cagliari, Italy
27 Hematology Unit,“A. Perrino” Hospital, Brindisi, Italy
28 Hematology Unit, Ospedale San Bortolo, Vicenza, Italy
29 Department of General Surgery and Medical-Surgical Specialties, Hematology Section, University of Catania, Italy
30 Department of Precision and Regenerative Medicine and Ionian Area, “Aldo Moro” University School of Medicine, Bari, Italy
Multiple Myeloma ODISSEY study Clinical Features

P65 | FUNCTIONAL HIGH RISK MULTIPLE MYELOMA IN THE ANTI-CD38 QUADRUPLET ERA: REDEFINITION THROUGH REAL WORLD DATA (171 Online Views)

S. Morè1|2, M. Offidani2, L. Corvatta3, T. Za4, F. Fazio5, M. Gherardini5, V. Bongarzoni6, B. Anaclerico6, L. Franceschini7, S. Ferraro8, L. Cupelli8, R. Spadano9, L. De Padua10, A. Rago11, S. Gentili12, R. Latagliata13, M. Garzia14, I. Cordone15, V. Mezzanotte7, E. Rossi4, F. Di Landro4, Z. Limongi5, E. Morsia1, A. Poloni1, M.T. Petrucci5

1 Department of Clinical and Molecular Sciences, DISCLIMO, Università Politecnica delle Marche, Ancona, Italy
2 Hematology Clinic, AOU delle Marche, Ancona, Italy
3 Internal Medicine, Ospedale E. Profili, Fabriano, Italy
4 Hematology Clinic, Policlinico Agostino Gemelli, Rome, Italy
5 Hematology Department of Translational and Precision Medicine, Azienda Policlinico Umberto I, Sapienza University of Rome, Italy
6 Department of Hematology, San Giovanni-Addolorata Hospital, Rome, Italy
7 Lymphoproliferative Diseases Unit, Tor Vergata University Hospital, Rome, Italy
8 Hematology, Ospedale Sant’Eugenio, Rome, Italy
9 Hematology Unit, Pescara Hospital, Italy
10 UOC di Ematologia, Trapianto di Cellule Staminali e Terapia Genica, Frosinone, Italy
11 UOSD Ematologia ASL Roma1, Italy
12 UOSD Ematologia Civitanova Marche AST Macerata, Italy
13 UOC Hematology, Santa Rosa Hospital, Viterbo, Italy
14 Department of Hematology, Hematology San Camillo Forlanini Hospital, Rome, Italy
15 IRCCS Istituto Nazionale Tumori Regina Elena- Dipartimento di Ricerca, Diagnostica Avanzata ed Innovazione Tecnologica-IFO, Rome, Italy
Functional high-risk NDMM Multiple Myeloma

P67 | TALQUETAMAB INDUCES DEEP RESPONSES IN HEAVILY PRE-TREATED PATIENTS WITH SYSTEMIC LIGHT-CHAIN AMYLOIDOSIS (200 Online Views)

T. Shragai1|2, M. Ganayem1, Y. Cohen1|2, I. Avivi1|2, E. Lebel3|4, N. Even-Gross Zohar3|4, N. Melamed1, M. Gatt3|4

1 Tel-Aviv Sourasky Medical Center, Israel
2 Tel-Aviv University, Israel
3 Hadassah Medical Center, Jerusalem, Israel
4 Hebrew University, Jerusalem, Israel
Multiple Myeloma AL amyloidosis Talquetamab

P68 | BIOPSY SPECIFIC CHARACTERISTICS ARE IMPORTANT IN DETECTING AMYLOID IN PATIENTS WITH AMYLOIDOSIS (169 Online Views)

F.G. Weverling1, A. Vinkenborg1, R.J. Leguit2, M.C. Minnema1

1 Department of Hematology, University Medical Center Utrecht, The Netherlands
2 Department of Pathology, University Medical Center Utrecht, The Netherlands
AL amyloidosis Multiple Myeloma CR-staining
1 - 25 of 80 items 1 2 3 4 > >> 
Navigate
For Authors
For Reviewers
For Advertisers
Education
Privacy
More
Copyright © 2026 by the Ferrata Storti Foundation | Web design ￫ | Development ￫
ISSN 0390-6078 print | ISSN 1592-8721 online